Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27361821 | 0.86 | TSHR (0.45) | ALDH1A1HPGDCYP3A4MAPK1CYP2C19 | |
| SCHEMBL8482557 | 0.81 | ALDH1A1 (0.49) | ALDH1A1HPGDMAPK1CYP2C19CYP2D6 | |
| SCHEMBL30016479 | 0.80 | PTPRC (0.54) | ALDH1A1HPGDCYP3A4CYP2C19CYP2C9 | |
| SCHEMBL18769941 | 0.80 | PTPRC (0.54) | ALDH1A1HPGDCYP3A4CYP2C19CYP2C9 | |
| SCHEMBL14011196 | 0.80 | KMT2A (0.49) | ALDH1A1CYP3A4CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL3157407 | 0.80 | KMT2A (0.47) | ALDH1A1CYP3A4MAPK1CYP2C19CYP2C9 | |
| SCHEMBL17080124 | 0.79 | KDM4E (0.52) | ALDH1A1HPGDCYP2C19CYP2C9CYP2D6 | |
| SCHEMBL11724672 | 0.79 | KMT2A (0.65) | ALDH1A1MAPK1CYP2C9KMT2AMEN1 | |
| SCHEMBL5043206 | 0.79 | HPGD (0.46) | ALDH1A1HPGDMAPK1CYP2C19CYP2D6 | |
| SCHEMBL8470680 | 0.78 | HPGD (0.53) | ALDH1A1HPGDCYP3A4MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241822-B1 | URAT1 INHIBITOR | NIPPON CHEMIPHAR CO (JP) | 2021-03-24 | — | — | EP | disclosed |
| CN-107108478-B | URAT1 inhibitors | 日本化学药品株式会社 | 2020-04-24 | — | — | CN | disclosed |
| US-10173990-B2 | URAT1 inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3241822-A1 | URAT1 INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-20170290795-A1 | URAT1 INHIBITOR | J-PHARMA CO., LTD. (JP) | 2017-10-12 | — | — | US | disclosed |
| US-5856503-A | ANTICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0778271-A2 | Aminoalkyl-substituted benzo-heterocyclic compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290795-A1 | URAT1 INHIBITOR | SLC10A1, XDH, URB2 | ALDH1A1 673/4885HPGD 4581/4885CYP3A4 3255/4885 |
| US-10173990-B2 | URAT1 inhibitor | SLC10A1, XDH, URB2 | ALDH1A1 672/4885HPGD 4601/4885CYP3A4 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.